BNP Paribas Financial Markets
NAVB

BNP Paribas Financial Markets’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

BNP Paribas Financial Markets’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,455
Closed -$38.7K – 3334
2015
Q4 		$38.7K Sell
1,455
-166
-10% -$5.76K ﹤0.01% 2981
2015
Q3 		$73.9K Buy
1,621
+994
+159% +$37.5K ﹤0.01% 2592
2015
Q2 		$20.2K Buy
627
+446
+246% +$13K ﹤0.01% 3051
2015
Q1 		$5.74K Buy
+181
New +$6.13K ﹤0.01% 3072
2014
Q4 		– Sell
-530
Closed -$14K – 3636
2014
Q3 		$14K Buy
530
+431
+435% +$11.4K ﹤0.01% 3398
2014
Q2 		$2.93K Buy
99
+80
+421% +$2.59K ﹤0.01% 2887
2014
Q1 		$621 Sell
19
-71
-79% -$2.69K ﹤0.01% 2990
2013
Q4 		$3.71K Sell
90
-1,553
-95% -$60.8K ﹤0.01% 3300
2013
Q3 		$87.1K Sell
1,643
-471
-22% -$27.5K ﹤0.01% 2438
2013
Q2 		$113K Buy
+2,114
New +$106K ﹤0.01% 2504

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BNP Paribas Financial Markets's NAVB Position: Q1 2016 in Review

BNP Paribas Financial Markets sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2016, closing a stake of 1,455 shares — an estimated $38.7K sold.

BNP Paribas Financial Markets first reported a position in NAVB in Q2 2013 and held it in 10 quarters. The position peaked at $113K in Q2 2013. 74 funds tracked by Wall St. Rank hold NAVB as of Q1 2016.

  • BNP Paribas Financial Markets reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2016 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 1,455 Navidea Biopharmaceuticals Inc. shares in Q1 2016, an estimated $38.7K.
  • BNP Paribas Financial Markets first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 10 quarters.
  • BNP Paribas Financial Markets's Navidea Biopharmaceuticals Inc. position peaked at $113K in Q2 2013.
  • 74 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2016.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2016, filed 22 Apr 2016.